Calculating Doses of VYXEOS
First Induction and Second Induction
Volume of each dose and number of vials for each course of therapy are calculated based on the patient’s body surface area (BSA) and the daunorubicin dose.1
- Each single-dose vial of VYXEOS contains 44 mg daunorubicin (2.2 mg/mL) and 100 mg cytarabine (5 mg/mL) and contains 20 mL after reconstitution2
- VYXEOS is administered intravenously as a 90-minute infusion1
|
First Induction2 |
Second Induction2 |
BSA (m2) |
mL per dose |
Vials per Course |
mL per dose |
Vials per Course |
1.3 | 26.0 | 6 | 26.0 | 4 |
1.4 | 28.0 | 6 | 28.0 | 4 |
1.5 | 30.0 | 6 | 30.0 | 4 |
1.6 | 32.0 | 6 | 32.0 | 4 |
1.7 | 34.0 | 6 | 34.0 | 4 |
1.8 | 36.0 | 6 | 36.0 | 4 |
1.9 | 38.0 | 6 | 38.0 | 4 |
2.0 | 40.0 | 6 | 40.0 | 4 |
2.1 | 42.0 | 9 | 42.0 | 6 |
2.2 | 44.0 | 9 | 44.0 | 6 |
2.3 | 46.0 | 9 | 46.0 | 6 |
2.4 | 48.0 | 9 | 48.0 | 6 |
2.5 | 50.0 | 9 | 50.0 | 6 |
2.6 | 52.0 | 9 | 52.0 | 6 |
2.7 | 54.0 | 9 | 54.0 | 6 |
|
First Induction2 |
BSA (m2) |
mL per dose |
Vials per Course |
1.3 | 26.0 | 6 |
1.4 | 28.0 | 6 |
1.5 | 30.0 | 6 |
1.6 | 32.0 | 6 |
1.7 | 34.0 | 6 |
1.8 | 36.0 | 6 |
1.9 | 38.0 | 6 |
2.0 | 40.0 | 6 |
2.1 | 42.0 | 9 |
2.2 | 44.0 | 9 |
2.3 | 46.0 | 9 |
2.4 | 48.0 | 9 |
2.5 | 50.0 | 9 |
2.6 | 52.0 | 9 |
2.7 | 54.0 | 9 |
|
Second Induction2 |
BSA (m2) |
mL per dose |
Vials per Course |
1.3 | 26.0 | 4 |
1.4 | 28.0 | 4 |
1.5 | 30.0 | 4 |
1.6 | 32.0 | 4 |
1.7 | 34.0 | 4 |
1.8 | 36.0 | 4 |
1.9 | 38.0 | 4 |
2.0 | 40.0 | 4 |
2.1 | 42.0 | 6 |
2.2 | 44.0 | 6 |
2.3 | 46.0 | 6 |
2.4 | 48.0 | 6 |
2.5 | 50.0 | 6 |
2.6 | 52.0 | 6 |
2.7 | 54.0 | 6 |
Please refer to the full Prescribing Information for VYXEOS for complete preparation and handling instructions, including BOXED Warning.
Consolidation
Volume of each dose and number of vials for each course of therapy are calculated based on the patient’s BSA and the daunorubicin dose.1
- Each single-dose vial of VYXEOS contains 44 mg daunorubicin and 100 mg cytarabine and contains 20 mL after reconstitution2
- VYXEOS is administered intravenously as a 90-minute infusion1
|
Consolidation2 |
BSA (m2) |
mL per dose |
Vials per Course |
1.3 | 17.1 | 2 |
1.4 | 18.5 | 2 |
1.5 | 19.8 | 2 |
1.6 | 21.1 | 4 |
1.7 | 22.4 | 4 |
1.8 | 23.7 | 4 |
1.9 | 25.0 | 4 |
2.0 | 26.4 | 4 |
2.1 | 27.7 | 4 |
2.2 | 29.0 | 4 |
2.3 | 30.3 | 4 |
2.4 | 31.6 | 4 |
2.5 | 33.0 | 4 |
2.6 | 34.3 | 4 |
2.7 | 35.6 | 4 |
Please refer to the full Prescribing Information for VYXEOS for complete preparation and handling instructions, including BOXED Warning.
References: 1. VYXEOS [package insert]. Palo Alto, CA: Jazz Pharmaceuticals. 2. Data on File (VYX-2022-022). Jazz Pharmaceuticals, Inc.